search
Back to results

Seroma Reduction and Drain Free Mastectomy (SARA)

Primary Purpose

Breast Cancer, Seroma, Wound Complication

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
No drain
With drain
Sponsored by
Zuyderland Medisch Centrum
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer focused on measuring Mastectomy, Drain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Older than 18 years
  • Female sex
  • Indication for mastectomy

Exclusion Criteria:

  • Patients undergoing breast conserving therapy
  • Patients undergoing modified radical mastectomy
  • Patients undergoing direct breast reconstruction
  • Unable to comprehend implications and extent of study and sign for informed consent
  • Patients with radiation therapy of unilateral breast in previous history

Sites / Locations

  • Zuyderland Medisch CentrumRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

With drain

No drain

Arm Description

Patients undergo mastectomy with flap fixation and low vacuum drainage.

Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.

Outcomes

Primary Outcome Measures

Seroma aspiration of clinically significant seroma
Proportion of patients undergoing seroma aspiration of clinically significant seroma Clinically significant seroma defined as: Wound healing is at risk due to seroma (wound break down, seroma leakage, necrosis) There is discomfort or pain caused by large amounts of seroma, characterised by tenseness of the skin. There is contaminated/ infected seroma and aspiration is necessary to treat infection. All patients that undergo seroma aspiration due to infection will also be treated with a one week course of Augmentin 625 mg 3 times daily.

Secondary Outcome Measures

Number of invasive interventions related to seroma or wound healing
Number of invasive interventions related to seroma or wound healing defined as: every aspiration of clinically significant seroma, incision and drainage of abscess or infected seroma and/or operative debriding of the wound.
Surgical site infection (SSI) rate
Surgical site infection (SSI) rate, defined as redness, pain, heat or swelling at the site of the incision or by the drainage of pus. Infection rate will be measured by A) the need for antibiotics, B) seroma aspiration due to infection or C) surgical drainage.
Cosmesis
Cosmesis rated by the patient using the numeric rating scale (NRS) every planned outpatient clinic visit.
Quality of life measured using the SF-12 Health Survey
Quality of life measured using the SF-12 Health Survey. Resulting in 2 scores: the Mental Component Summary (MCS) and the Physical Component Summary (PCS). Both range between values of 0-100 with a score of 50 representing values of a standard population
The number of outpatient department visits
The number of outpatient department visits
Experienced pain: NRS
Experienced wound pain and pain at the drain site by the patient using the NRS with a scale range from 0-10

Full Information

First Posted
July 24, 2019
Last Updated
July 6, 2023
Sponsor
Zuyderland Medisch Centrum
search

1. Study Identification

Unique Protocol Identification Number
NCT04035590
Brief Title
Seroma Reduction and Drain Free Mastectomy
Acronym
SARA
Official Title
Seroma Reduction and Drain Free Mastectomy
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 26, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zuyderland Medisch Centrum

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To prove that omitting drains after mastectomy and flap fixation does not contribute to higher incidence of seroma formation and therefore reducing patient disutility such as seroma aspirations and visits to the outpatient clinic, as well as reducing seroma related wound complications.
Detailed Description
Rationale: Seroma formation, a collection of serous fluid containing blood plasma and/or lymph fluid, is a common complication in breast cancer surgery and can lead to delayed wound healing, infection, skin flap necrosis, patient discomfort and repeated visits to the outpatient clinic and therefore extensive research has been done to further elucidate the pathophysiology and prevention of seroma formation. Promising results have resulted from studies focusing on flap fixation in order to reduce the incidence of seroma and seroma aspirations. Mastectomy with flap fixation is becoming standard practice and is currently combined with closed-suction drainage. Closed-suction drainage is considered gold standard for reducing seroma formation after breast cancer surgery. However, evidence shows that closed-suction drainage is insufficient in preventing seroma formation. One might wonder if there is still a place for closed-suction drainage after mastectomy if flap fixation is performed. The promising results in flap fixation could exclude drainage systems in breast cancer surgery. However, the available data consist of small case series and therefore a large randomized controlled trial is needed for it to be widely implemented. To our knowledge, no randomized controlled trial has been conducted comparing flap fixation with and without closed-suction drainage with seroma aspiration as the primary outcome. The investigators hypothesize that flap fixation with closed suction drainage does not cause a significant lower incidence of seroma aspirations, when compared to flap fixation alone. The investigators also expect that patients without drainage will experience significantly less discomfort and comparable rates of surgical site infections. Objective: To prove that omitting drains after mastectomy and flap fixation does not contribute to higher incidence of seroma formation and therefore reducing patient disutility such as seroma aspirations and visits to the outpatient clinic, as well as reducing seroma related wound complications. Study design: Prospective randomized controlled trial Study population: Female patients > 18 years diagnosed with invasive breast cancer or DCIS (ductal carcinoma in situ) with an indication to perform mastectomy Intervention (if applicable): Mastectomy with flap fixation using sutures with closed suction drainage Mastectomy with flap fixation using sutures without closed suction drainage Main study parameters/endpoints: Patients undergoing seroma aspiration (clinically significant seroma (CSS)). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be informed about the study before inclusion in the outpatient clinic. Informed consent will be obtained in the outpatient clinic a week after patients were initially informed. Postoperative check-ups will be done more frequently. Standard postoperative check-ups are planned at 2 weeks and 3 months. Additional study postoperative check-ups: 6 weeks, 6 months. Therefore, patients will be required to undergo two additional check-ups. During out patients' visits, patients will hand in a questionnaire scale regarding cosmesis, pain and quality of life. Patients will be clinically examined as they usually would be.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Seroma, Wound Complication
Keywords
Mastectomy, Drain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Study design is a randomized controlled trial. All patients are > 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center Sittard. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS. Follow up will be performed until 6 months after surgery. Patients will be evaluated in the out patient clinic 1 week, 6 weeks, 3 months and 6 months.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
With drain
Arm Type
Active Comparator
Arm Description
Patients undergo mastectomy with flap fixation and low vacuum drainage.
Arm Title
No drain
Arm Type
Experimental
Arm Description
Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
Intervention Type
Procedure
Intervention Name(s)
No drain
Intervention Description
Mastectomy with flap fixation without low vacuum drainage
Intervention Type
Procedure
Intervention Name(s)
With drain
Intervention Description
Mastectomy with flap fixation with low vacuum drainage
Primary Outcome Measure Information:
Title
Seroma aspiration of clinically significant seroma
Description
Proportion of patients undergoing seroma aspiration of clinically significant seroma Clinically significant seroma defined as: Wound healing is at risk due to seroma (wound break down, seroma leakage, necrosis) There is discomfort or pain caused by large amounts of seroma, characterised by tenseness of the skin. There is contaminated/ infected seroma and aspiration is necessary to treat infection. All patients that undergo seroma aspiration due to infection will also be treated with a one week course of Augmentin 625 mg 3 times daily.
Time Frame
During first six months post-operative
Secondary Outcome Measure Information:
Title
Number of invasive interventions related to seroma or wound healing
Description
Number of invasive interventions related to seroma or wound healing defined as: every aspiration of clinically significant seroma, incision and drainage of abscess or infected seroma and/or operative debriding of the wound.
Time Frame
During first six months post-operative
Title
Surgical site infection (SSI) rate
Description
Surgical site infection (SSI) rate, defined as redness, pain, heat or swelling at the site of the incision or by the drainage of pus. Infection rate will be measured by A) the need for antibiotics, B) seroma aspiration due to infection or C) surgical drainage.
Time Frame
During the first six postoperative months
Title
Cosmesis
Description
Cosmesis rated by the patient using the numeric rating scale (NRS) every planned outpatient clinic visit.
Time Frame
During the first six postoperative months
Title
Quality of life measured using the SF-12 Health Survey
Description
Quality of life measured using the SF-12 Health Survey. Resulting in 2 scores: the Mental Component Summary (MCS) and the Physical Component Summary (PCS). Both range between values of 0-100 with a score of 50 representing values of a standard population
Time Frame
During the first six postoperative months
Title
The number of outpatient department visits
Description
The number of outpatient department visits
Time Frame
During the first six months postoperative.
Title
Experienced pain: NRS
Description
Experienced wound pain and pain at the drain site by the patient using the NRS with a scale range from 0-10
Time Frame
During the first six months postoperative

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Older than 18 years Female sex Indication for mastectomy Exclusion Criteria: Patients undergoing breast conserving therapy Patients undergoing modified radical mastectomy Patients undergoing direct breast reconstruction Unable to comprehend implications and extent of study and sign for informed consent Patients with radiation therapy of unilateral breast in previous history
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
James van Bastelaar, MD, PhD
Phone
+31884591870
Email
j.vanbastelaar@zuyderland.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Merel Spiekerman van Weezelenburg, MD
Phone
+31884591870
Email
m.spiekermanvanweezelenburg@zuyderland.nl
Facility Information:
Facility Name
Zuyderland Medisch Centrum
City
Sittard
State/Province
Limburg
ZIP/Postal Code
6162 BG
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James van Bastelaar, MD
Phone
+31641227350
Email
j.vanbastelaar@zuyderland.nl

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32767988
Citation
de Rooij L, van Kuijk SMJ, van Haaren ERM, Janssen A, Vissers YLJ, Beets GL, van Bastelaar J. A single-center, randomized, non-inferiority study evaluating seroma formation after mastectomy combined with flap fixation with or without suction drainage: protocol for the Seroma reduction and drAin fRee mAstectomy (SARA) trial. BMC Cancer. 2020 Aug 7;20(1):735. doi: 10.1186/s12885-020-07242-0.
Results Reference
derived

Learn more about this trial

Seroma Reduction and Drain Free Mastectomy

We'll reach out to this number within 24 hrs